FMCG and Pharmaceutical Counterfeits: Consumer Protection and Brand Liability in Nepal

Two layers, one problem

The counterfeit cosmetic, medicine or packaged food violates two legal regimes at once. The IP layer — trademark infringement: the fake uses the brand's mark without permission; the remedies are the PDTA's (fines up to NPR 100,000, confiscation) through DOI and police enforcement. The consumer-protection layer — the sale of counterfeit, adulterated or substandard goods: prohibited by the Consumer Protection Act 2075 (2018), enforced by the Department of Commerce, Supplies and Consumer Protection (DoCSCP), with penalties scaled to the harm (including imprisonment for serious offences) and sector regulators (the Department of Drug Administration for medicines) adding licensing and quality regimes.

The layers differ in purpose and power: IP enforcement protects the brand's exclusive rights; consumer protection protects the public — and the latter's penalties for dangerous goods exceed the IP ceilings substantially. The strategic consequence: for counterfeit cosmetics and medicines, the consumer-protection complaint is often the sharper instrument — and the two filed together compound.

The brand's own liability exposure

The uncomfortable half of the topic: brands in counterfeit-affected sectors carry their own duties. Channel diligence: where your distribution chain sells fakes alongside genuine goods, the brand's supply-chain controls are the first question any regulator, court or journalist asks — the authorised-distributor programme, traceability and channel audits are compliance, not just strategy. Labelling compliance: genuine products missing required consumer information (ingredients, manufacturing/expiry, pricing under the applicable rules) are their own consumer-protection violation — the fake's packaging is sometimes more compliant than the real product's, which is an indefensible position in any proceeding. The distinguishability duty: where consumers cannot tell genuine from fake, the brand's anti-counterfeit investment (security features, verification channels, education) becomes part of the liability and reputation analysis.

The practical duty stack for FMCG and pharma brands in Nepal: authorised-distributor programmes with contractual anti-counterfeit terms and audits; batch/lot traceability that can answer 'was this unit genuine?' authoritatively; compliant labelling verified against the consumer-protection and sector requirements; anti-counterfeit packaging (security features proportionate to the risk); and consumer education — the verification guides that let buyers check, which protects consumers first and the brand's market share as a consequence.

• Channel diligence is a compliance duty, not optional strategy
• Genuine products must out-comply the fakes on labelling
• Verification infrastructure serves consumers and liability alike

The combined enforcement playbook

For a counterfeit problem in these sectors, the playbook layers the instruments by target:

1. 1

   Document across both layers

   Test purchases and IP evidence (mark, specimens, volumes) plus consumer-protection evidence (product safety issues, labelling defects, harm reports). The second file is what activates DoCSCP and the sector regulators.

2. 2

   File the consumer-protection complaint

   DoCSCP (and the Department of Drug Administration for medicines) — the complaint citing the sale of counterfeit/substandard goods, with the safety evidence. These channels move fast on dangerous goods and carry the higher penalties.

3. 3

   Run the IP track in parallel

   The DOI/police route (infringement, confiscation) and the customs alert program (border interception) — the market-clearing and supply-chain instruments.

   The raid process: police coordination
4. 4

   Protect the consumers, visibly

   Verification guides, authorised-seller lists, batch-check channels — the consumer-facing layer that reduces harm (the statutory purpose) and rebuilds the trust the fakes damaged (the commercial purpose).

   Identifying fake vs real goods

The Bill-era strengthening

The Industrial Property Bill 2082 carries the anti-counterfeit strengthening Nepal's reviews have asked for: enhanced border measures, stronger penalties and seizure powers, licence revocations for infringing businesses — the architecture the Kathmandu Post's reporting on the draft described as targeting 'brand piracy' with 'stringent measures'. Combined with the Consumer Protection Act's regime, the direction is clear: the legal cost of counterfeit FMCG and pharmaceuticals is rising.

For brands, the posture this guide recommends is permanent regardless of statute: comply above the minimum, verify your channel, protect your consumers, and enforce across both layers. The sectors where counterfeits kill — medicines first — are where the state's tolerance is lowest and the tools are sharpest. Brands that lead there set the enforcement climate everyone else inherits.